Qingdao FTZ boosts biopharmaceutical, health sectors

Qingdao Conson Development Group, Sino Biopharmaceutical Limited, and the Marine Biomedical Research Institute of Qingdao signed a cooperation agreement in Qingdao on March 6.

The agreement marks the beginning of in-depth cooperation in the biopharmaceutical and health industries within the Qingdao Area of the China (Shandong) Pilot Free Trade Zone (Qingdao FTZ).

Qingdao Conson Development Group, Sino Biopharmaceutical Limited, and the Marine Biomedical Research Institute of Qingdao forge collaborative relations in Qingdao FTZ. [Photo/WeChat account: qingdaozimao]

The biopharmaceutical industry is important to the economy of Qingdao FTZ, and through this tripartite agreement, Qingdao aims to develop a distinctive marine life and health industry.

Over the years, Qingdao FTZ has been leading the way in marine genomics research. It has hosted the International Marine Genomics Alliance Conference for three years in a row and collaborated on 883 projects with 178 research institutes globally.

Moreover, the BGI Research Institute has established a cutting-edge "China Science and Technology" innovation base in Qingdao FTZ, enabling the development of the world's largest marine gene bank.

Looking ahead, leveraging the zone's institutional innovations, the focus will be on creating a collaborative platform for the advancement of modern marine and life health industries.